Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Immunogenicity and Safety of Incepta's Trastuzumab vs Herclon in Healthy Men
NCT06886659Phase 1Completed
- Sponsor
- Incepta Pharmaceuticals Ltd.
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of trastuzumab in breast cancer, gastric cancer (GC) and gastroesophageal junction cancer (2 arms), sponsored by Incepta Pharmaceuticals Ltd. Primary endpoints: Maximum Plasma Concentration at 71 days, Area Under the Concentration-Time Curve from time zero to last measurable concentration at 71 days and 3 more. Started Jan 2024; status: completed.
02
Drugs
03
Conditions
breast cancergastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT06886659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06886659.